Novo Nordisk slumps on tougher 2026 financial outlook
Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.
Patent losses hit Novartis hard, but CEO has a plan
Novartis CEO Vas Narasimhan says the company is equipped to ride out "the largest patent expiry" in its history," but 2026 will still be tricky.
Fears US drug pricing deal will weigh heavy on the NHS
The UK confirms that the cost of the drug pricing deal with the US, initially around £1bn over three years, will be borne by the health department.
FDA knocks back AstraZeneca's self-injected lupus drug
FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.
UK will cover transport costs for children with cancer
Families of young people with cancer in England will have the costs of travelling to medical appointments covered under a new funding scheme.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Book your tickets and join the PM Society for the 40th PM Aw...
Tickets are on sale for the 40th anniversary of the PM Awards
The Pharmaceutical Manufacturing and Packaging Congress (PHA...
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity